Nonlinear Dynamics, a global provider of bioinformatics, has announced a co-marketing agreement with Agilent Technologies to mutually promote and distribute integrated analysis solutions
The agreement is centred on synergies between the Agilent 2100 bioanalyzer 'lab-on-a-chip' platform and Nonlinear's TL120 DM software.
Financial terms were not disclosed.
The first stage of the agreement will see technical development to automate the export of electropherogram data from Agilent's bioanalyzer Expert software for analysis with Nonlinear's TotalLab TL120 DM for the purpose of varietal identification.
This collaborative solution will enable researchers to import DNA, RNA and protein sample data from the 2100 bioanalyzer for further relationship comparison, archiving and data mining within TL120 DM.
Fred Strohmeier, general manager of Agilent Technologies Liquid Phase Analysis Business, said, "Recognising the evolutionary challenges facing life science researchers to analyse, store and mine increasing volumes of RNA, DNA and assay data, we are pleased to be working with Nonlinear to enable users to discover more using the bioanalyzer platform".
"Our product portfolio also incorporates the applications of mass spectrometry, microarrays, gas and liquid chromatography".
"Because Nonlinear already has various technologies available for use in these markets, there is potential for further collaboration in the future." Will Dracup, group CEO of Nonlinear Dynamics, said: "Agilent's reputation as the world's leading measurement company, coupled with the natural synergy between the Bioanalyzer and TotalLab platform, makes them an excellent partner".
"Users will benefit from the application of independently developed, industry-tested hardware and software combined for the first time as a powerful integrated solution."
